Evercore ISI Initiates Coverage on ProQR Therapeutics (NASDAQ:PRQR)

Stock analysts at Evercore ISI initiated coverage on shares of ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) in a research note issued on Tuesday, MarketBeat reports. The firm set an "outperform" rating and a $5.00 price target on the biopharmaceutical company's stock. Evercore ISI's price objective suggests a potential upside of 151.26% from the stock's current price.

Several other equities research analysts have also issued reports on the stock. Oppenheimer assumed coverage on shares of ProQR Therapeutics in a research note on Friday, January 10th. They issued an "outperform" rating and a $15.00 price target on the stock. HC Wainwright upped their price objective on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a report on Friday, March 14th. Chardan Capital reissued a "buy" rating and set a $4.00 price target on shares of ProQR Therapeutics in a report on Friday, March 14th. Finally, Citigroup upgraded shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 target price on the stock in a research report on Monday, March 10th. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $8.75.

ProQR Therapeutics Stock Up 15.7 %

NASDAQ PRQR traded up $0.27 during trading on Tuesday, reaching $1.99. 1,450,411 shares of the stock traded hands, compared to its average volume of 611,137. ProQR Therapeutics has a fifty-two week low of $1.07 and a fifty-two week high of $4.62. The stock's 50-day moving average price is $1.56 and its 200 day moving average price is $2.48. The firm has a market cap of $209.37 million, a price-to-earnings ratio of -6.22 and a beta of 0.35.

Hedge Funds Weigh In On ProQR Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of PRQR. Jane Street Group LLC bought a new stake in shares of ProQR Therapeutics during the fourth quarter worth $30,000. Invesco Ltd. bought a new stake in ProQR Therapeutics in the fourth quarter valued at approximately $32,000. Alpine Global Management LLC acquired a new stake in ProQR Therapeutics during the 4th quarter valued at approximately $39,000. Two Sigma Securities LLC bought a new position in ProQR Therapeutics during the 4th quarter worth approximately $40,000. Finally, Vontobel Holding Ltd. acquired a new position in shares of ProQR Therapeutics in the 1st quarter worth approximately $48,000. Institutional investors own 32.65% of the company's stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).